Molecular Testing in Pulmonary Tumors
作者： Jeffrey J. Tanguay , Shirin Karimi , David M. Hwang , Ming-Sound Tsao
DOI: 10.1007/978-1-4899-8050-2_13
关键词:
摘要: The past decade has seen a dramatic revolution in the treatment of lung cancer, resulting large part from discovery specific molecular alterations that render tumors with these abnormalities amenable to targeted therapies. Many affect intracellular signaling pathways promote growth and survival tumor cells inhibit apoptosis. As result, pathologists must be aware increasing number tests now being implemented as routine diagnostic algorithms for personalizing cancers. Here, we review are commonly present cancers discuss currently clinical use, an emphasis on epidermal factor receptor mutations anaplastic lymphoma kinase-1 (ALK) rearrangements non-small cell cancer. Other emerging, potentially targetable aberrations also discussed, including those small carcinoma.
springer.com
sci-hub.st 参考文章(155)
Antonio Marchetti, Lara Felicioni, Sara Malatesta, Maria Grazia Sciarrotta, Luigi Guetti, Antonio Chella, Patrizia Viola, Carmela Pullara, Felice Mucilli, Fiamma Buttitta, Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations Journal of Clinical Oncology. ,vol. 29, pp. 3574- 3579 ,(2011) , 10.1200/JCO.2011.35.9638
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Moran, Amelia Insa, Filippo De Marinis, Romain Corre, Isabel Bover, Alfonso Illiano, Eric Dansin, Javier De Castro, Michele Milella, Noemi Reguart, Giuseppe Altavilla, Ulpiano Jimenez, Mariano Provencio, Miguel Angel Moreno, Josefa Terrasa, Jose Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Domine, Olivier Molinier, Julien Mazieres, Nathalie Baize, Rosario Garcia-Campelo, Gilles Robinet, Delvys Rodriguez-Abreu, Guillermo Lopez-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, Pierre Bombaron, Reyes Bernabe, Alessandra Bearz, Angel Artal, Enrico Cortesi, Christian Rolfo, Maria Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, Jose Luis Ramirez, Jose Javier Sanchez, Miguel Angel Molina, Miquel Taron, Luis Paz-Ares, None, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology. ,vol. 13, pp. 239- 246 ,(2012) , 10.1016/S1470-2045(11)70393-X
Jun Matsubayashi, Toshitaka Nagao, Norihiko Ikeda, Fred R. Hirsch, Yasufumi Kato, Nir Peled, Murry W. Wynes, Koichi Yoshida, Marta Pardo, Celine Mascaux, Tatsuo Ohira, Masahiro Tsuboi, Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations Journal of Thoracic Oncology. ,vol. 5, pp. 1551- 1558 ,(2010) , 10.1097/JTO.0B013E3181E9DA60
Rodney J. Landreneau, Phouthone Keohavong, Mary Ann A DeMichele, Alea C. Melacrinos, Robert J. Weyant, Jill M. Siegfried, Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clinical Cancer Research. ,vol. 2, pp. 411- 418 ,(1996)
David Jackman, William Pao, Gregory J. Riely, Jeffrey A. Engelman, Mark G. Kris, Pasi A. Jänne, Thomas Lynch, Bruce E. Johnson, Vincent A. Miller, Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 28, pp. 357- 360 ,(2010) , 10.1200/JCO.2009.24.7049
I G Wilson, Inhibition and facilitation of nucleic acid amplification. Applied and Environmental Microbiology. ,vol. 63, pp. 3741- 3751 ,(1997) , 10.1128/AEM.63.10.3741-3751.1997
Seiji Yano, Wei Wang, Qi Li, Kunio Matsumoto, Haruko Sakurama, Takahiro Nakamura, Hirokazu Ogino, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka, Hisanori Uehara, Tetsuya Mitsudomi, Yasushi Yatabe, Toshikazu Nakamura, Saburo Sone, Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations Cancer Research. ,vol. 68, pp. 9479- 9487 ,(2008) , 10.1158/0008-5472.CAN-08-1643
Jian Yu, Susan Kane, Jiong Wu, Elisa Benedettini, Daiqiang Li, Cynthia Reeves, Gregory Innocenti, Randy Wetzel, Katherine Crosby, Alison Becker, Michelle Ferrante, Wan Cheung Cheung, Xiqiang Hong, Lucian R. Chirieac, Lynette M. Sholl, Herbert Haack, Bradley L. Smith, Roberto D. Polakiewicz, Yi Tan, Ting-Lei Gu, Massimo Loda, Xinmin Zhou, Michael J. Comb, Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clinical Cancer Research. ,vol. 15, pp. 3023- 3028 ,(2009) , 10.1158/1078-0432.CCR-08-2739
William Pao, Theresa Y Wang, Gregory J Riely, Vincent A Miller, Qiulu Pan, Marc Ladanyi, Maureen F Zakowski, Robert T Heelan, Mark G Kris, Harold E Varmus, KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib PLOS Medicine. ,vol. 2, ,(2005) , 10.1371/JOURNAL.PMED.0020017
Liang Cheng, Riley E Alexander, Gregory T MacLennan, Oscar W Cummings, Rodolfo Montironi, Antonio Lopez-Beltran, Harvey M Cramer, Darrell D Davidson, Shaobo Zhang, Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology. ,vol. 25, pp. 347- 369 ,(2012) , 10.1038/MODPATHOL.2011.215